Suneva Medical Inc.'s Silhouette InstaLift Wins Best Thread Lift Treatment in NewBeauty's 2022 Beauty Awards

SAN DIEGO, April 13, 2022 /PRNewswire/ -- Suneva Medical, Inc. ("Suneva" or the "Company"), an innovative medical technology company using regenerative medicine to change the standard of care in aesthetic treatments, announced that its Silhouette InstaLift®, a non-surgical thread lift, has won the Best Thread Lift Treatment title in NewBeauty's 2022 Beauty Awards. Silhouette InstaLift uses collagen-stimulating absorbable sutures that offer patients immediate and lasting results with minimal recovery time.

NewBeauty announced the winners of its 12th annual NewBeauty Awards, a collection of the 365 most innovative products and treatments taking the beauty industry by storm, in a release on April 5 and in the publication's Spring-Summer issue, currently on newsstands nationwide. This year marks NewBeauty's biggest Awards yet, with the introduction of numerous categories, including breakthroughs in sustainability. In judging products annually, NewBeauty editors must confirm that the winning products and services deliver on their claims, offer solutions to the biggest beauty problems, and make those who use them look and feel like the best versions of themselves.

"The Suneva team is honored to have Silhouette InstaLift named amongst so many other beauty industry leaders and innovators," said Pat Altavilla, Chief Executive Officer of Suneva. "Winning this NewBeauty award proves just how valued our FDA-approved procedure is to providers and patients."

The Silhouette InstaLift procedure takes place in a physician's office and is done in less than an hour. A patient will walk out with an immediate facial lift thanks to Silhouette Instalift's unique bi-directional micro-cone technology. Over time patients continue to see results as Silhouette InstaLift boosts natural collagen production, adding volume to the cheeks and mid-face.

"A growing number of patients come to me looking for a natural and rejuvenated-looking face, without wanting to undergo serious surgery. And though some fillers can lift the face to a degree, patients want to avoid looking overfilled from too many fillers to get the lift they need," said Dr. Kimberly Butterwick, Dermatologist and Silhouette InstaLift provider in San Diego, California. "I've utilized Silhouette InstaLift in my practice for over 5 years, and it is a trusted way to achieve the natural, long lasting results my patients are looking for—without the downtime of a traditional facelift."

"The Silhouette InstaLift treatment is easy for providers to learn and offer to our patients. Regenerative aesthetic options are extremely popular in my practice, with more and more people understanding the benefits of harnessing the body's natural abilities to fight aging," said Dr. Steven Yoelin, a board-certified ophthalmologist, medical aesthetics industry expert, corporate strategic advisor, clinical researcher, medical trainer and Silhouette InstaLift provider in Orange County, California. "My Silhouette InstaLift patients rave about the immediate and natural lift with minimal downtime."

On January 12, 2022, Suneva Medical and Viveon Health Acquisition Corp. (NYSE American: VHAQ) ("Viveon Health" or "VHAQ"), a special purpose acquisition company, announced that they entered into a definitive merger agreement. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE American under the symbol "RNEW."  

*A study of 100 patients treated with Silhouette InstaLift. Results were based on patient satisfaction surveys sent at 1 week post-treatment (n=28) and at 3 months posttreatment (n=47). Improvement in midfacial deficits was evaluated by clinical reviewers at 3 and 6 months post-treatment using a volume deficit scale (0=none, 1=minimal, 2=mild, 3=moderate, 4=significant, and 5=severe) (n=91). The majority of patients started with an average deficit of 3.Model is a real patient treated with Silhouette InstaLift by Tam Nguyen, MD. Individual technique and results may vary. †18% PGA/82% PLLA.

References: 1. Silhouette InstaLift® Instructions for Use. Sinclair Pharmaceuticals; 2019., 2. Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys. 2011;49(12):832-864. 4. Nestor MS, Ablon G, Andriessen A, et al. Expert consensus on absorbable advanced suspension technology for facial tissue repositioning and volume enhancement. J Drugs Dermatol. 2017;16(7):661-666.

Silhouette InstaLift is the only non-surgical rejuvenating procedure that uses advanced Micro-Suspension Technology™ to offer immediate and lasting results.* The procedure takes under an hour and is done in a provider's office. InstaLift also has minimal downtime, with most signs of treatment (ex: bruising, swelling, and tenderness at the treatment site) dissipating within 24–48 hours. Patients can get right back to their activities and enjoy an instant lift in the cheeks, while adding volume over time for long lasting results. Suneva's Micro Suspension Technology is comprised of micro cones that are placed in the deepest layer of mid-facial skin. It delivers an immediate lift and gradually restores lost facial volume of the mid face by activating patient's own natural collagen production for a more youthful appearance that continues to improve over time. The sutures and cones are made from poly lactic-co-glycolic acid (PLGA), a well-known biomedical copolymer that is biocompatible and biodegradable ^1,2,†. Learn more about Silhouette InstaLift at https://instalift.com/.

About Suneva Medical, Inc.

Suneva Medical, Inc., headquartered in San Diego, CA, is a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva Medical offers a portfolio of products to address the impact of the aging process to deliver solutions that leverage the body's own restorative capacity. The product portfolio is composed of several "only" and "first to market" solutions with both FDA PMA approval and 510(k) clearance. For more information, visit https://www.sunevamedical.com/.

Important Information About the Proposed Business Combination and Where to Find It
In connection with the proposed business combination, Viveon Health will file a registration statement on Form S-4 containing a proxy statement/prospectus (the "Form S-4") with the U.S. Securities and Exchange Commission (SEC). The Form S-4 will include a proxy statement to be distributed to holders of Viveon Health's common stock in connection with the solicitation of proxies for the vote by Viveon Health's stockholders with respect to the proposed transaction and other matters as described in the Form S-4, as well as the prospectus relating to the offer of securities to be issued to Suneva's stockholders in connection with the proposed business combination. After the Form S-4 has been filed and declared effective, Viveon Health will mail a definitive proxy statement, when available, to its stockholders. Investors, security holders and other interested parties are urged to read the Form S-4, any amendments thereto and any other documents filed with the SEC carefully and in their entirety when they become available because they will contain important information about Viveon Health, Suneva and the proposed business combination. Additionally, Viveon Health will file other relevant materials with the SEC in connection with the business combination. Copies may be obtained free of charge at the SEC's web site at www.sec.gov. Securityholders of Viveon Health are urged to read the Form S-4 and the other relevant materials when they become available before making any voting decision with respect to the proposed business combination because they will contain important information about the business combination and the parties to the business combination. The information contained on, or that may be accessed through, the websites referenced in this press release is not incorporated by reference into, and is not a part of, this press release.

Participants in the Solicitation
Viveon Health and its directors and executive officers may be deemed participants in the solicitation of proxies from Viveon Health's stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in Viveon Health will be included in the Form S-4 for the proposed business combination and be available at www.sec.gov. Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed business combination when available. Information about Viveon Health's directors and executive officers and their ownership of Viveon Health's common stock is set forth in Viveon Health's prospectus, dated December 22, 2020, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the direct and indirect interests of the participants in the proxy solicitation will be included in the proxy statement/prospectus pertaining to the proposed business combination when it becomes available. These documents can be obtained free of charge from the SEC's web site at www.sec.gov.

Suneva and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Viveon Health in connection with the proposed business combination. A list of the names of such directors and executive officers and information regarding their interests in the proposed business combination will be included in the Form S-4 for the proposed business combination.

Forward-Looking Statements
Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "target," "believe," "expect," "will," "shall," "may," "anticipate," "estimate," "would," "positioned," "future," "forecast," "intend," "plan," "project," "outlook" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding: Mr. Brower's instrumentality in fundraising and partnership development; expansion of Suneva in the regenerative aesthetic market; Suneva's growth within its announced SPAC deal and continued evolution and adoption of Suneva's regenerative medical products; and the combined company's shares being traded on the NYSE. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Viveon Health's and Suneva's current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement; (2) the institution or outcome of any legal proceedings that may be instituted against Viveon Health and/or Suneva following the announcement of the merger agreement and the transactions contemplated therein; (3) the inability of the parties to complete the proposed business combination, including due to failure to obtain approval of the stockholders of Viveon Health or Suneva, certain regulatory approvals, or satisfy other conditions to closing in the merger agreement; (4) the occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement or could otherwise cause the transaction to fail to close; (5) the failure to meet the minimum cash requirements of the merger agreement due to Viveon Health stockholder redemptions and the failure to obtain replacement financing; (6) the inability to complete a concurrent PIPE; (7) the impact of COVID-19 pandemic on Suneva's business and/or the ability of the parties to complete the proposed business combination; (8) the inability to obtain or maintain the listing of Viveon Health's shares of common stock on the NYSE American following the proposed business combination; (9) the risk that the proposed business combination disrupts current plans and operations as a result of the announcement and consummation of the proposed business combination; (10) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition and the ability of Suneva to grow and manage growth profitably and retain its key employees; (11) costs related to the proposed business combination; (12) changes in applicable laws or regulations; (13) the possibility that Suneva may be adversely affected by other economic, business, and/or competitive factors; (14) the amount of redemption requests made by Viveon Health's stockholders; (15) changes in the competitive landscape, including the introduction of competitive products or improvements in existing products; and (16) other risks and uncertainties indicated from time to time in the final prospectus of Viveon Health for its initial public offering dated December 22, 2020 filed with the SEC and the Form S-4 relating to the proposed business combination, including those under "Risk Factors" therein, and in Viveon Health's other filings with the SEC. Viveon Health and Suneva caution that the foregoing list of factors is not exclusive. Viveon Health and Suneva caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Viveon Health and Suneva do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law. Neither Viveon Health nor Suneva gives any assurance that the combined company will achieve its expectations.

No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

SOURCE Suneva® Medical, Inc.